We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05626634
Recruitment Status : Recruiting
First Posted : November 25, 2022
Last Update Posted : January 13, 2023
Information provided by (Responsible Party):
Longboard Pharmaceuticals

Brief Summary:
The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.

Condition or disease Intervention/treatment Phase
Developmental and Epileptic Encephalopathy Dravet Syndrome Lennox-Gastaut Syndrome Drug: LP352 Phase 2

Detailed Description:

This Phase 2, multicenter, open-label, multiple-dose extension clinical study is designed to evaluate long-term safety of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201.

The study consists of a Screening Period (Day -1) and a 50-week open-label Treatment Period that includes a 15-day Up-titration Period (during which time subjects will titrate up to their highest tolerated doses) and an open-label Maintenance Period (48 weeks). The Treatment Period will be followed by a Down-titration/Taper Period (up to 15 days) and Follow-up Period (14 days after completion of down-titration). The starting dose of up-titration will be 6 mg TID. The target final maintenance doses are 6 mg TID, 9 mg TID, and 12 mg TID after a 15-day up-titration period, if tolerated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks
Actual Study Start Date : November 8, 2022
Estimated Primary Completion Date : October 2024
Estimated Study Completion Date : October 2024

Arm Intervention/treatment
Experimental: LP352
Subjects will be titrated up to highest tolerated dose of LP352 during a 15-day period, followed by a 48-week maintenance period and a 15-day taper/down titration period.
Drug: LP352
LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube

Primary Outcome Measures :
  1. Treatment-emergent Adverse Events [ Time Frame: Baseline up to Week 52 ]
    Incidence and severity of treatment-emergent adverse events, including serious adverse events and adverse events leading to study discontinuation and clinically significant changes in vital signs, physical examination endpoints, clinical safety laboratory values and ECGs

  2. Columbia-Suicide Severity Rating Scale (C-SSRS) Response [ Time Frame: Baseline up to Week 52 ]
    Type of Suicidal Ideation, Intensity (1 - 5, with 5 being most severe), Suicidal Behavior

  3. Patient Health Questionnaire-9 Total Score and Question 9 Score [ Time Frame: Baseline up to Week 52 ]
    Severity Rating Scale: 0 - 27; higher scores indicate greater severity of depressive disorder

Secondary Outcome Measures :
  1. Percent Change from Baseline in Observed Countable Motor Seizure Frequency During the Treatment Period [ Time Frame: Baseline to Week 50 ]
    Baseline Used for Seizure Frequency = Baseline from Study LP352-201 and Baseline from Study LP352-202

  2. Proportion of Subjects with > 50% Reduction in Total Seizures During the Treatment Period [ Time Frame: Baseline to Week 50 ]
  3. Percent Reduction in Individual Seizure Type During the Treatment Period [ Time Frame: Baseline to Week 50 ]
  4. Proportion of Subjects Requiring Rescue Medication During the Treatment Period [ Time Frame: Baseline to Week 50 ]
  5. Percent Change from Baseline in the Number of Episodes of Status Epilepticus During the Treatment Period [ Time Frame: Baseline to Week 50 ]
  6. Percent of Subjects with Countable Motor Seizure-free Days During the Treatment Period [ Time Frame: Baseline to Week 50 ]
  7. Percentage Change from Baseline in Non-motor and Difficult to Count Seizures [ Time Frame: Baseline to Week 50 ]
  8. LGS: Percentage Change from Baseline in the Frequency of Observed Drop Seizures Over the Treatment Period [ Time Frame: Baseline to Week 50 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or non-pregnant, non-lactating female, age 12 to 65 years who have satisfactorily completed study LP352-201
  2. Diagnosis of Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and epileptic encephalopathy
  3. The patient/parent/caregiver is able and willing to attend study visits, complete the diary and take study drug as instructed

Exclusion Criteria:

  1. Had an SAE in Study LP352-201 that was definitely, probably, or possibly related to exposure to study drug
  2. Current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction, stroke, pulmonary arterial hypertension or abnormal blood pressure
  3. Has glaucoma, renal impairment, liver disease or any other medical condition that would affect study participation or pose a risk to the subject
  4. Current or recent history of moderate or severe depression, anorexia nervosa, bulimia or at risk of suicidal behavior
  5. Currently taking anorectic agents, monoamine oxidase inhibitors; serotonin agonists or antagonists including fenfluramine, atomoxetine, vortioxetine, or other medications for weight loss
  6. Positive test result on the drug screen, except tetrahydrocannabinol (THC) for patients taking prescribed cannabidiol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05626634

Layout table for location contacts
Contact: Longboard Study Contact 858-999-8858 clinicalstudies@longboardpharma.com

Show Show 24 study locations
Sponsors and Collaborators
Longboard Pharmaceuticals
Layout table for investigator information
Principal Investigator: Dennis J Dlugos, MD Children's Hospital of Philadelphia
Layout table for additonal information
Responsible Party: Longboard Pharmaceuticals
ClinicalTrials.gov Identifier: NCT05626634    
Other Study ID Numbers: LP352-202
First Posted: November 25, 2022    Key Record Dates
Last Update Posted: January 13, 2023
Last Verified: December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Longboard Pharmaceuticals:
CDKL5 deficiency disorder
developmental and epileptic encephalopathy
Dravet Syndrome
Lennox-Gastaut Syndrome
treatment resistant epilepsy
tuberous sclerosis complex
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Epilepsies, Myoclonic
Lennox Gastaut Syndrome
Pathologic Processes
Central Nervous System Diseases
Nervous System Diseases
Epilepsy, Generalized
Epileptic Syndromes
Genetic Diseases, Inborn